You’re using a public version of DrugPatentWatch with free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Italy: These 1 Drugs Face Patent Expirations and Generic Entry From 2024 - 2025

DrugPatentWatch^® Estimated Loss of Exclusivity Dates in Italy

The content of this page is licensed under a Creative Commons Attribution 4.0 International License.

Preferred citation:
Friedman, Yali, "Italy: These 1 Drugs Face Patent Expirations and Generic Entry From 2024 - 2025" DrugPatentWatch.com thinkBiotech, 2024 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral

These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.

When can AEMCOLO (rifamycin) generic drug versions launch?

Generic name: rifamycin
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 25, 2024
Generic Entry Controlled by: Italy Patent MI20041295
Patent Title: COMPOSIZIONI FARMACEUTICHE ANTIMICROBICHE ORALI

AEMCOLO is a drug marketed by Redhill. There are four patents protecting this drug.

This drug has twenty-eight patent family members in twenty-one countries.

See drug price trends for AEMCOLO.

The generic ingredient in AEMCOLO is rifamycin. There are eleven drug master file entries for this API. Additional details are available on the rifamycin profile page.

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.